Literature DB >> 28940056

Causes and prognostic factors for early death in patients with acute promyelocytic leukemia treated with single-agent arsenic trioxide.

Jinxiao Hou1, Shuye Wang1, Yingmei Zhang2, Dachuan Fan3, Haitao Li1, Yiju Yang4, Fei Ge1, Wenyi Hou1, Jinyue Fu1, Ping Wang1,5, Hongli Zhao1,6, Jiayue Sun1, Kunpeng Yang1, Jin Zhou1,2, Xiaoxia Li7.   

Abstract

Early death (ED) is one of the most critical issues involved in the current care of patients with acute promyelocytic leukemia (APL). Factors identified as independent predictors of ED varied among published studies. We retrospectively analyzed the incidence, causes, and prognostic factors of ED in a series of 216 patients with newly diagnosed APL who received arsenic trioxide (ATO) as induction therapy. Multivariate logistic regression analysis was used to determine the association of clinical factors with overall ED, hemorrhagic ED, death within 7 days, and death within 8-30 days. In total, 35 EDs (16.2%) occurred that were caused by hemorrhage, differentiation syndrome (DS), infection, and other causes, in order of prevalence. The independent prognostic factors for overall ED and death within 8-30 days were the same and included serum creatinine level, Eastern Cooperative Oncology Group (ECOG) score, sex, and fibrinogen level. The risk factors for hemorrhagic ED and death within 7 days were similar and included serum creatinine level, ECOG score, and white blood cell count, while hemorrhagic ED was also associated with D-dimer. Our findings revealed a high rate of ED, and the causes of ED were similar to those among patients who received ATRA-based therapy. Increased creatinine level was the most powerful predictor, and an ECOG score greater than 2 was another strong prognostic factor for all four types of ED.

Entities:  

Keywords:  Acute promyelocytic leukemia; Arsenic trioxide; Early death; Prognostic factor

Mesh:

Substances:

Year:  2017        PMID: 28940056     DOI: 10.1007/s00277-017-3130-7

Source DB:  PubMed          Journal:  Ann Hematol        ISSN: 0939-5555            Impact factor:   3.673


  5 in total

1.  miR-139-5p Regulates the Proliferation of Acute Promyelocytic Leukemia Cells by Targeting MNT.

Authors:  Yueyue Fu; Limin Li; Jinxiao Hou; Huibo Li; Chengfang Lv; Hongjuan Yu; Xiaoqian Zhang; Mengyuan Xu; Mingwen Zhang; Hongbin Meng; Jie Liu; Xin Lian; Jiawei Feng; Jin Zhou
Journal:  J Oncol       Date:  2021-04-16       Impact factor: 4.375

Review 2.  Blood Parameters in Treatment with Arsenic Trioxide in Acute Promyelocytic Leukemia: A Systematic Review.

Authors:  Mehdi Mohammadi Kanesbi; Lida Jarahi; Mohammad Reza Keramati
Journal:  Int J Hematol Oncol Stem Cell Res       Date:  2020-04-01

3.  Hypercalcemia and acute pancreatitis in a male patient with acute promyelocytic leukemia and pulmonary tuberculosis.

Authors:  Ali S Abdullah; Ahmad M Adel; Radwa M Hussein; Mohammed Aj Abdullah; Anil Yousaf; Deena Mudawi; Shehab F Mohamed; Abdulqadir J Nashwan; Dina Soliman; Feryal Ibrahim; Mohamed A Yassin
Journal:  Acta Biomed       Date:  2018-04-03

4.  Severe Wernicke encephalopathy and acute pancreatitis due to all-trans-retinoic acid and arsenic trioxide during treatment of acute promyelocytic leukaemia: a case report.

Authors:  Yan Jiang; Linhua Ji
Journal:  J Int Med Res       Date:  2020-09       Impact factor: 1.671

5.  Absolute Circulating Leukemic Cells as a Risk Factor for Early Bleeding Events in Patients with Non-High-Risk Acute Promyelocytic Leukemia.

Authors:  Yanru Pei; Mingyue Shi; Juanjuan Song; Xiaona Niu; Shengjie Wei; Liurui Dou; Mengyu Xiao; Dan Li; Fangfang Xu; Yanliang Bai; Kai Sun
Journal:  Cancer Manag Res       Date:  2021-05-21       Impact factor: 3.989

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.